BVF Inc’s Galmed Pharmaceuticals GLMD Stock Holding History

BVF Inc’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,488	Closed	-$261K	–	70
2023 Q2	$261K	Hold	7,488	–	–	0.01%	66
2023 Q1	$575K	Sell	7,488 -2,177	-23%	-$234K	0.02%	70
2022 Q4	$870K	Sell	9,665 -333	-3%	-$21.8K	0.04%	73
2022 Q3	$558K	Hold	9,998	–	–	0.02%	78
2022 Q2	$1.22M	Hold	9,998	–	–	0.06%	73
2022 Q1	$2.86M	Hold	9,998	–	–	0.11%	69
2021 Q4	$3.27M	Hold	9,998	–	–	0.12%	72
2021 Q3	$5.02M	Hold	9,998	–	–	0.2%	65
2021 Q2	$5.47M	Hold	9,998	–	–	0.21%	60
2021 Q1	$6.17M	Hold	9,998	–	–	0.23%	56
2020 Q4	$5.6M	Hold	9,998	–	–	0.22%	52
2020 Q3	$6.35M	Hold	9,998	–	–	0.35%	51
2020 Q2	$8.6M	Sell	9,998 -182	-2%	-$154K	0.53%	43
2020 Q1	$6.34M	Hold	10,180	–	–	0.59%	34
2019 Q4	$10.6M	Hold	10,180	–	–	0.8%	29
2019 Q3	$8.76M	Hold	10,180	–	–	0.92%	32
2019 Q2	$13.5M	Sell	10,180 -256	-2%	-$330K	1.47%	22
2019 Q1	$15.3M	Hold	10,436	–	–	1.72%	21
2018 Q4	$12.8M	Buy	10,436 +650	+7%	+$1.14M	1.68%	21
2018 Q3	$23.9M	Hold	9,786	–	–	2.1%	18
2018 Q2	$21M	Buy	+9,786	New	+$14.2M	2.05%	19

Other funds holding GLMD

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TFGT

TS Financial Group (TSFG) Lake Forest, Illinois $794M AUM 24.65% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BVF Inc's GLMD Position: Q3 2023 in Review

BVF Inc sold out of Galmed Pharmaceuticals (GLMD) in Q3 2023, closing a stake of 7,488 shares — an estimated $261K sold.

BVF Inc first reported a position in GLMD in Q2 2018 and held it in 21 quarters. The position peaked at $23.9M in Q3 2018. 16 funds tracked by Wall St. Rank hold GLMD as of Q3 2023.

BVF Inc reported no remaining Galmed Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
BVF Inc sold 7,488 Galmed Pharmaceuticals shares in Q3 2023, an estimated $261K.
BVF Inc first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 21 quarters.
BVF Inc's Galmed Pharmaceuticals position peaked at $23.9M in Q3 2018.
16 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2023.

Based on BVF Inc's 13F filing for Q3 2023, filed 14 Nov 2023.